

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

NOVADEL PHARMA INC
Form 8-K
November 13, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) NOVEMBER 12, 2002

NOVADEL PHARMA INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE

000-23399

22-2407152

(STATE OR OTHER
JURISDICTION OF
FORMATION)

(COMMISSION
FILE NUMBER)

(IRS EMPLOYER
IDENTIFICATION NO.)

31 STATE HIGHWAY 12

FLEMINGTON, NJ

08822

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (908) 782-3431

(FORMER NAME OR FORMER ADDRESS, IF CHANGES SINCE LAST REPORT)

ITEM 5. OTHER EVENTS.

On November 12, 2002, Novadel Pharma Inc., a Delaware corporation (the "Company"), extended the expiration date of its Redeemable Common Stock Purchase Warrants (the "Warrants") from November 18, 2002 to November 18, 2003.

The terms of the Warrants that have been extended are identical and otherwise will remain unchanged. The Warrants are and will continue to allow the holder thereof to purchase one share of Common Stock of the Company at an exercise price of \$5.80 per share.

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

Holders of the Warrants need not take any action in connection with the extension of the expiration date of the Warrants. The existing certificates will continue to represent the right to acquire shares of the Company's common stock on the same terms and conditions (other than the expiration date) as were in effect prior to the extension.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA INFORMATION AND EXHIBITS.

(c) Exhibits

99 Press Release dated November 13, 2002.

ITEM 9. REGULATION FD DISCLOSURE.

Exhibit 99 hereto sets forth a press release issued by the Company to report the extension of the Warrants and additional information about the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly authorized and caused the undersigned to sign this Report on the Registrant's behalf.

NOVADEL PHARMA INC.

By: /s/ Harry A. Dugger, III

Name: Harry A. Dugger, III
Title: President and Chief Executive
Officer

Dated: November 13, 2002